Publications by authors named "D L Asher"
Delandistrogene moxeparvovec is an rAAVrh74 vector-based gene transfer therapy that delivers a transgene encoding delandistrogene moxeparvovec micro-dystrophin, an engineered, functional form of dystrophin shown to stabilize or slow disease progression in DMD. It is approved in the US and in other select countries. Two serious adverse event cases of immune-mediated myositis (IMM) were reported in the phase Ib ENDEAVOR trial (NCT04626674).
View Article and Find Full Text PDFIntroduction: Consensus contouring guidelines for intensity-modulated-radiation-therapy (IMRT) of patients with locally advanced cervix cancer (LACC) advise including the whole uterus in the target volume and adding generous planning-target-volumes (PTVs) to account for motion uncertainties of the gross-tumor-volume (GTV). The primary objective of this analysis was to assess the interfractional GTV motions using a magnetic-resonance-image (MRI) guided-Radiation-Therapy (MRgRT) system to investigate the margins required for MRgRT treatments.
Methods: 125 daily set-up MRIs from five patients with LACC who received MRgRT were analyzed.
Article Synopsis
- Longer periods between headache episodes may allow the nervous system to recover better, possibly enhancing patients' quality of life and disease status.
- The study, PROMISE-2, analyzed data from over 1,000 chronic migraine patients to examine the relationship between the length of interictal periods (time between headaches) and various patient-reported health outcomes.
- Results showed that patients with interictal periods longer than 21 days reported significantly better improvements in headache impact, overall health status, and bothersome symptoms compared to those with shorter periods.
Background: Modern literature has brought into question if wear of tibial inserts made from conventional or highly crosslinked polyethylene (HXL PE) is still a factor limiting longevity of total knee arthroplasty (TKA) in the mid- to long-term. It is the objective of this study to determine: 1) most common causes of mid- to long-term TKA failure, 2) the prevalence of delamination, and 3) the medial/lateral linear wear rates of conventional and HXL PE tibial inserts retrieved in the mid- to long-term.
Methods: A tibial insert retrieval cohort of 107 inserts (79 conventional, 28 HXL PE) with a minimum time in situ of 6.
Article Synopsis
- - Duchenne muscular dystrophy (DMD) is a serious genetic condition linked to the absence of a protein called dystrophin, leading to severe mobility and respiratory problems, and is evaluated in the phase 3 EMBARK trial using a gene therapy called delandistrogene moxeparvovec.
- - The trial involved boys aged 4 to 8 with DMD who received either the gene therapy or a placebo, but results showed no significant improvement in the primary measure of motor function (NSAA score) after 52 weeks.
- - Although the primary endpoint wasn't met, some secondary measures did show improvement in muscle function and expression of micro-dystrophin, with a notable number of adverse events recorded but